Effects of dapagliflozin monotherapy and combined aerobic exercise on skeletal muscle mitochondrial quality control and insulin resistance in type 2 diabetes mellitus rats

Effects of dapagliflozin monotherapy and combined aerobic exercise on skeletal muscle mitochondrial quality control and insulin resistance in type 2 diabetes mellitus rats

Type 2 diabetes mellitus (T2DM) is a prevalent, chronic metabolic disease. Sodium-glucose cotransporter-2 (SGLT2) inhibitors and aerobic exercise (AE) have shown promise in mitigating insulin resistance (IR) and T2DM. This study investigated the effects of dapagliflozin (Dapa) monotherapy and combin...

Full description

Bibliographic Details
Main Authors:	Liangzhi Zhang, Hengjun Lin, Xudong Yang, Jipeng Shi, Xiusheng Sheng, Lifeng Wang, Ting Li, Helong Quan, Xia Zhai, Wei Li
Format:	Article
Language:	English
Published:	Elsevier 2023-12-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	Dapagliflozin Aerobic exercise Type 2 diabetes mellitus Insulin resistance Skeletal muscle Mitochondrial quality control
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332223016505

Similar Items

Exercise mitigates Dapagliflozin-induced skeletal muscle atrophy in STZ-induced diabetic rats
by: Xudong Yang, et al.
Published: (2023-07-01)

Dapagliflozin's effect on serum homocysteine in patients with hypertension complicated with insulin resistance
by: Xiaoqian Yu, et al.
Published: (2023-05-01)

Correction: Exercise mitigates Dapagliflozin-induced skeletal muscle atrophy in STZ-induced diabetic rats
by: Xudong Yang, et al.
Published: (2023-08-01)

Aerobic Exercise Prevents Chronic Inflammation and Insulin Resistance in Skeletal Muscle of High-Fat Diet Mice
by: Nan Li, et al.
Published: (2022-09-01)

Dapagliflozin Protects Methamphetamine-Induced Cardiomyopathy by Alleviating Mitochondrial Damage and Reducing Cardiac Function Decline in a Mouse Model
by: Shanqing He, et al.
Published: (2022-07-01)

Dapagliflozin Promotes Neovascularization by Improving Paracrine Function of Skeletal Muscle Cells in Diabetic Hindlimb Ischemia Mice Through PHD2/HIF-1α Axis
by: Dyah Ari Nugrahaningrum, et al.
Published: (2020-08-01)

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
by: Olga Yuryevna Sukhareva, et al.
Published: (2016-01-01)

The Effect of either Aerobic Exercise Training or Chrysin Supplementation on Mitochondrial Biogenesis in Skeletal Muscle of High Fat Diet-Induced Obese Mice
by: Kyung-Il Kim, et al.
Published: (2019-11-01)

An improvement in skeletal muscle mitochondrial capacity with short‐term aerobic training is associated with changes in Tribbles 1 expression
by: Rick B. Vega, et al.
Published: (2020-06-01)

EFFECTS OF A SINGLE BOUT OF AEROBIC EXERCISE ON SKELETAL MUSCLE PROTEIN TURNOVER IN MICE
by: Yong-An Kim, et al.
Published: (2017-12-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
by: Yvo J.M. op den Kamp, et al.
Published: (2022-12-01)

Pharmacological inhibition of dynamin‐related protein 1 attenuates skeletal muscle insulin resistance in obesity
by: Benjamin A. Kugler, et al.
Published: (2021-04-01)

Appropriate Dose of Dapagliflozin Improves Cardiac Outcomes by Normalizing Mitochondrial Fission and Reducing Cardiomyocyte Apoptosis After Acute Myocardial Infarction
by: Fan ZG, et al.
Published: (2022-06-01)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
by: Kim HC, et al.
Published: (2023-04-01)

Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension
by: Yi Tang, et al.
Published: (2022-04-01)

Effectiveness of dapagliflozin as an insulin adjunct in type 1 diabetes: a semi-mechanistic exposure-response model
by: Victor Sokolov, et al.
Published: (2023-10-01)

The Mitochondrial Proteomic Signatures of Human Skeletal Muscle Linked to Insulin Resistance
by: Rikke Kruse, et al.
Published: (2020-07-01)

Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function
by: Martins Amanda R, et al.
Published: (2012-02-01)

Chitosan Versus Dapagliflozin in a Diabetic Cardiomyopathy Mouse Model
by: Georgică Târtea, et al.
Published: (2024-02-01)

Transcriptomic Analysis of Human Skeletal Muscle in Response to Aerobic Exercise and Protein Intake
by: Xueqing Zeng, et al.
Published: (2023-08-01)

Comparison of Cardioprotective Effects of Dapagliflozin and Trimetazidine in the Model of Doxorubicin-Cyclophosphamide Cardiotoxicity
by: A. A. Avagimyan, et al.
Published: (2023-11-01)

Role of mitochondria-associated endoplasmic reticulum membranes in insulin sensitivity, energy metabolism, and contraction of skeletal muscle
by: Bianca Nieblas, et al.
Published: (2022-10-01)

Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway
by: Liuran Li, et al.
Published: (2021-05-01)

Exercise Augments the Effect of SGLT2 Inhibitor Dapagliflozin on Experimentally Induced Diabetic Cardiomyopathy, Possible Underlying Mechanisms
by: Mamdouh Eldesoqui, et al.
Published: (2022-07-01)

Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation
by: Pei-Ling Hsieh, et al.
Published: (2022-09-01)

Dapagliflozin Ameliorates Neural Damage in the Heart and Kidney of Diabetic Mice
by: Ionuț Donoiu, et al.
Published: (2023-12-01)

Practice of Dapagliflozin Application in Patients with Type 2 Diabetes Mellitus
by: L.V. Shkala, et al.
Published: (2015-08-01)

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
by: Rhona Johnston, et al.
Published: (2017-01-01)

Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome
by: Hwee-Yeong Ng, et al.
Published: (2021-11-01)

Use of dapagliflozin in patients with advanced diabetic kidney disease
by: Hyun Sun Park, et al.
Published: (2018-09-01)

Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
by: Carlos Escobar, et al.
Published: (2023-10-01)

Dapagliflozin attenuates hypoxia/reoxygenation-caused cardiac dysfunction and oxidative damage through modulation of AMPK
by: Kun-Ling Tsai, et al.
Published: (2021-02-01)

Early initiation of Dapagliflozin and its effect on health related quality of life in acute heart failure: a randomised controlled trial
by: Syedah Fauzia Fatima Gilani, et al.
Published: (2024-03-01)

COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN
by: V. I. Petrov, et al.
Published: (2016-04-01)

Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives
by: Nashar K, et al.
Published: (2022-11-01)

Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
by: Haroon Aziz, et al.
Published: (2023-06-01)

Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage
by: Jianhua Zeng, et al.
Published: (2023-03-01)

Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
by: Sanjay Kalra, et al.
Published: (2015-01-01)

Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring
by: Wilfried Mullens, et al.
Published: (2020-10-01)

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin
by: Schwartz SS, et al.
Published: (2016-03-01)